Mammary tumors are the most frequent type of cancer in female dogs as in women. Besides that, its cells share similar features and can be used to comparative studies and screening of antineoplastic agents. Epigenetic targets are highlighted as potential and innovative therapy against cancer. Both histone deacetylases (HDACs) and bromodomain and extraterminal proteins (BET) inhibitors have been shown to be efficient in types of cancer such as lymphoma, leukemia and NUT midline carcinomas. In breast cancer, few studies have observed good effects of these inhibitors. Furthermore, when applying individually, some issues may arise, including incomplete efficacy and drug resistance. Thus, new strategies to overcome these limitations are necessary and one of the possibilities is to test the combined effect of HDAC-BET inhibition using a dual inhibitor. We propose, in this Project, an 8-month internship abroad in Buchmann Institute for Molecular Life Sciences at the Goethe University Frankfurt am Main, Germany to test a new and unpublished dual HDAC-BET inhibitor on breast cancer cells using 2D and 3D in vitro models. We believe that the period will be enough to perform the analysis and the data acquired will determine a possible new strategy for future therapies targeting breast cancer. After that, we will observe the effects of the new dual HDAC-BET inhibitor using canine mammary cancer cells from our laboratory in Brazil finding to a comparative approach which will allow us to elucidate a possible treatment strategy for mammary cancer in both women and dogs.
News published in Agência FAPESP Newsletter about the scholarship: